Instruction for use: Saltos

Active substance Salbutamol

ATX Code R03CC02 Salbutamol

Pharmacotherapeutic group:

Beta-adrenergic agonist

The nosological classification (ICD-10)

J43 Emphysema

Interstitial emphysema, Emphysema, Chronic lung disease, Chronic obstructive pulmonary disease, Obstructive pulmonary emphysema, Chronic pulmonary emphysema, Chronic obstructive pulmonary emphysema

J44 Other chronic obstructive pulmonary disease

Allergic bronchitis, Bronchitis asthma, Asthmatic bronchitis, wheeze bronchitis, Bronchitis is an obstructive, bronchi disease, Shortness of sputum in acute and chronic respiratory diseases, Cough in inflammatory diseases of the lung and bronchus, Reversible airflow obstruction, Reversible obstructive airway disease, Obstructive bronchitis disease, Obstructive lung disease, Obstructive bronchitis, Spastic bronchitis, Chronic lung disease, Chronic nonspecific lung diseases, Chronic obstructive pulmonary disease, Chronic obstructive bronchitis, Chronic obstructive airway disease, Chronic obstructive pulmonary disease, Restrictive lung pathology

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

Structure and Composition

Film-coated tablets with prolonged action Table 1.

salbutamol hemisuccinate 0.00723 g

Excipients: sodium chloride; low molecular weight polyvinyl Medical; sodium carboxymethylcellulose; magnesium stearate; cellulose acetate

plastic vials at 30 or 60 pcs .; in box 1 bottle, or in blisters of 10 pcs .; in box 3 of the package.

pharmachologic effect

bronchodilatory.

Selectively stimulates beta2-adrenergic receptors.

pharmacodynamics

It relaxes the smooth muscles of the bronchi, prevents the development of bronchospasm, restores breathing against the background of established bronchospasm, prevents nocturnal asthma.

Pharmacokinetics

Well absorbed from the gastrointestinal tract. Controlled release of salbutamol hemisuccinate after taking the pill inside allows you to create and maintain long-term effective therapeutic concentration in the blood. T1 / 2 -. 6 hours excreted by the kidneys. The therapeutic effect lasts for 12-14 hours.

Indications Saltos® drug

Diseases accompanied by reversible airflow obstruction: bronchial asthma, chronic obstructive bronchitis, emphysema; prevention of nocturnal asthma attacks.

Contraindications

Hypersensitivity, severe heart failure, cardiac arrhythmias (paroxysmal tachycardia, ventricular arrythmia politopnye et al.); impaired function of the kidneys and liver.

Pregnancy and breast-feeding

Contraindicated.

Side effects

Tremor (especially hands), tachycardia.

Interaction

Not allowed simultaneous reception with non-selective beta-blockers.

Dosing and Administration

Inside, as a whole, without chewing, in 0.00723 1 g once a day in the afternoon. The daily dose may be increased to 0,01446-0,02169 g (1st reception morning, following an interval of 12 or 8 hours, respectively). To prevent attacks of breathlessness at night - 0.00723 g for 3-4 hours before bedtime.

Precautionary measures

Caution must be exercised in patients with hyperthyroidism.

special instructions

Swallow whole, without chewing. Damaged tablets suitable for use.

Storage conditions Saltos® drug

In a dry, dark place at a temperature no higher than 25 ° C.

Keep out of the reach of children.

The shelf life of the drug Saltos®

4 years.

Do not use beyond the expiration date printed on the package.